Figure 2: In vitro evaluation of OMCP-mutIL-2.
From: Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy
(a) In vitro flow cytometrically evaluated activation of A/J spleen-derived lymphocyte subsets after 36 h of culture in 100 IUe ml−1 of cytokines or OMCP-mutIL-2 construct. Graph demonstrating one representative histogram plot and median fluorescent intensity (MFI) ±s.e.m. across 5–7 separate experiments, containing one to two mice per group per experiment, as a graph in right upper corner. (b) In vitro activation of human peripheral blood lymphocyte subsets after 36 h of culture in 100 IUe ml−1 of cytokines or OMCP-mutIL-2 construct. Graph demonstrating one representative histogram plot and MFI±s.e.m. across 4–5 separate experiments as graph in right upper corner. Proliferation of C57BL/6 wild-type (c) or C57BL/6NKG2D−/− (d) splenic lymphocyte subsets after 5-day culture in 1,000 IUe ml−1 of cytokines or OMCP-mutIL-2. Graph demonstrating one representative histogram plot of four separate experiments. Composite MFI±s.e.m. shown as graph below the CFSE histogram plots. Comparison of MFI performed by ANOVA for multiple comparisons and unpaired t-test for each individual group. ns P>0.05; *P<0.05; **P<0.01; ***P<0.001; black=saline; blue=wtIL-2, red=OMCP-mutIL-2, green=mutIL-2.
